CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus

Acta Neurologica Scandinavica

Volumn 116, Issue 5, 2007, Pages 333-339

  Agren Wilsson A ^a   Lekman, A ^b   Sjoberg W ^a   Rosengren, L ^b   Blennow, K ^b   Bergenheim, A T ^a   Malm, J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Beta amyloid1 42; Biomarkers; Idiopathic normal pressure hydrocephalus; Neurofilament protein light; Sulfatide; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; SULFATIDE; TAU PROTEIN;

ADULT; AGED; ARTICLE; BINSWANGER ENCEPHALOPATHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; NORMOTENSIVE HYDROCEPHALUS; PROTEIN ANALYSIS; SHUNTING;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID PRESSURE; CEREBROSPINAL FLUID SHUNTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL HYPERTENSION; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SULFOGLYCOSPHINGOLIPIDS; TAU PROTEINS; UP-REGULATION;

EID: 35148888199     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00890.x     Document Type: Article

References (35)

1. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005 3 (Suppl S4 16.
2. Wikkelso C, Andersson H, Blomstrand C, Lindqvist G, Svendsen P. Normal pressure hydrocephalus. Predictive value of the cerebrospinal fluid tap-test. Acta Neurol Scand 1986 73:566 73.
3. Malm J, Kristensen B, Karlsson T, Fagerlund M, Elfverson J, Ekstedt J. The predictive value of cerebrospinal fluid dynamic tests in patients with idiopathic adult hydrocephalus syndrome. Arch Neurol 1995 52:783 9.
4. Bech-Azeddine R, Waldemar G, Knudsen GM, et al. Idiopathic normal-pressure hydrocephalus: evaluation and findings in a multidisciplinary memory clinic. Eur J Neurol 2001 8:601 11.
5. Akai K, Uchigasaki S, Tanaka U, Komatsu A. Normal pressure hydrocephalus: neuropathological study. Acta Pathol Jpn 1987 37:97 110.
6. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H. Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke 1997 28:1423 9.
7. Makarov DV, Carter HB. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 2006 176:2383 5.
8. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001 58:373 9.
9. Tarnaris A, Watkins LD, Kitchen ND. Biomarkers in chronic adult hydrocephalus. Cerebrospinal Fluid Res 2006 3:11.
10. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992 85:103 6.
11. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996 67:2013 18.
12. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003 987:25 31.
13. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998 50:1122 7.
14. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2006 21:291 5.
15. Tullberg M, Mansson JE, Fredman P, et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000 69:74 81.
16. Kapaki EN, Paraskevas GP, Tzerakis NG, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 2007 14:168 73.
17. Malm J, Lundkvist B, Eklund A, Koskinen LO, Kristensen B. CSF outflow resistance as predictor of shunt function. A long-term study. Acta Neurol Scand 2004 110:154 60.
18. Malm J, Kristensen B, Stegmayr B, Fagerlund M, Koskinen LO. Three-year survival and functional outcome of patients with idiopathic adult hydrocephalus syndrome. Neurology 2000 55:576 8.
19. Bennett DA, Wilson RS, Gilley DW, Fox JH. Clinical diagnosis of Binswanger's disease. J Neurol Neurosurg Psychiatry 1990 53:961 5.
20. Davidsson P, Fredman P, Månsson J, Svennerholm L. Determination of ganglioside and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique. Clin Chim Acta 1991 197:105 15.
21. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995 26:231 45.
22. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000 285:49 52.
23. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999 56:673 80.
24. Bech RA, Juhler M, Waldemar G, Klinken L, Gjerris F. Frontal brain and leptomeningeal biopsy specimens correlated with cerebrospinal fluid outflow resistance and B-wave activity in patients suspected of normal-pressure hydrocephalus. Neurosurgery 1997 40:497 502.
25. Golomb J, Wisoff J, Miller D, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000 68:778 81.
26. Kudo T, Mima T, Hashimoto R, et al. Tau protein is a potential biological marker for normal pressure hydrocephalus. Psychiatry Clin Neurosci 2000 54:199 202.
27. Tarvonen-Schroder S, Blennow K, Lekman A, Fredman P, Raiha I, Sourander L. Gangliosides and sulfatide in cerebrospinal fluid in leukoaraiosis. Dement Geriatr Cogn Disord 1997 8:174 9.
28. Malm J, Kristensen B, Ekstedt J, Wester P. CSF concentration gradients of monoamine metabolites in patients with hydrocephalus. J Neurol Neurosurg Psychiatry 1994 57:1026 33.
29. Blennow K, Wallin A, Gottfries CG, Mansson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 1993 5:5 15.
30. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001 310:173 86.
31. Fredman P, Lekman A. Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders. Neurochem Res 1997 22:1071 83.
32. Blennow K. CSF biomarkers for mild cognitive impairment. J Int Med 2004 256:224 34.
33. Poca M, Mataro M, Sahuquillo J, Catalan R, Ibanez J, Galard R. Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2001 70:298 304.
34. Tisell M, Tullberg M, Mansson JE, Fredman P, Blennow K, Wikkelso C. Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and idiopathic normal pressure hydrocephalus. Eur J Neurol 2004 11:17 23.
35. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003 21:79 96.